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Background: Interleukin-17 (IL-17A) is a mainly pro-inﬂammatory cytokine, and IL-17 signaling impli-
cates in the development of allergic asthma. The polymorphism rs2275913 in the promoter region of the
IL-17A gene has in previous studies been associated with asthma susceptibility. The objective was to
evaluate the association between IL-17A rs2275913 (-197G>A) polymorphism and post-bronchiolitis
asthma and/or allergic rhinitis in a prospective 11e13 years post-bronchiolitis follow-up.
Methods: 166 previously healthy full-term infants, hospitalized for bronchiolitis at age less than
6 months, were invited to follow-up visits at the ages of 5e7 years and 11e13 years. Asthma diagnoses
and presumptive symptoms, allergic rhinitis and use of inhaled corticosteroids (ICS) were registered.
Blood samples for IL-17A rs2275913 (-197G>A) polymorphismwere obtained during hospitalization or at
the 5e7 years control visit.
Results: There were no signiﬁcant differences between children with the wild GG and variant GA or AA
genotype in the severity of bronchiolitis during hospitalization or in the outcomes until the age 5e7
years. At 11e13 years of age, children with the variant GA or AA genotype had signiﬁcantly less often
current asthma, use of ICSs during last 12 months or allergic rhinitis than those with the wild GG ge-
notype. The ICS use during last 12 months retained the statistical signiﬁcance in adjusted analyses
(adjusted OR 0.25), whereas current asthma and allergic rhinitis marginally lost it.
Conclusions: The IL-17A rs2275913 (-197G>A) polymorphism decreased the risk of post-bronchiolitis
asthma at 11e13 years of age, but not earlier in life, in the present prospective, long-term follow-up
study.
Copyright © 2017, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Asthma constitutes a global pediatric problem, and genetic
susceptibility seems to play an important role in its development.1
Inhaled corticosteroids (ICS) for maintenance and bronchodilators
for exacerbations are the established drugs for asthma treatment.
Allergic rhinitis frequently co-exists with asthma and may even
share a common genetic basis.2l, Department of Pediatrics,
ivirta).
ety of Allergology.
rgology. Production and hosting by ElseBronchiolitis is usually caused by respiratory syncytial virus
(RSV) being characterized by virus-induced inﬂammation of the
bronchioles.3 Infants hospitalized with bronchiolitis are at
increased risk of both recurrent wheezing and childhood asthma.3
Allergic children may present with impaired antiviral responses
leading to more pronounced inﬂammation during respiratory
infection and further to higher risk of subsequent wheezing.4
The interleukin-17 (IL-17) family contains six members, and
among them IL-17A and IL-17F share the highest protein sequence
homology.5 The IL-17 family members are pro-inﬂammatory cyto-
kines predominantly secreted by T helper 17 (Th17) cells.6 In
addition, there is evidence that IL-17A induces local Th17 cell
production in RSV bronchiolitis and some autoimmune diseases.7,8vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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neutrophils in the tissue, and IL-17A may have an impact on the
balance between eosinophilic and neutrophilic inﬂammation in the
airways.9,10 Thus, the IL-17A gene is a potential candidate gene for
post-bronchiolitis asthma susceptibility.
We have previously followed-up 166 children hospitalized for
bronchiolitis at less than 6 months of age. The control visits were
organized at 5e7 years11 and 11e13 years of ages. Blood samples for
genetic studies were obtained during hospitalization and at the
5e7 years visits.12 In previous publications from this post-
bronchiolitis cohort, IL-10 polymorphism was associated with
rhinovirus etiology of bronchiolitis,13 atopy and asthma at pre-
school age,14 and asthma and lung function reduction at early
school age.15
The aim of this study was to evaluate the associations between
IL-17A rs2275913 (-197G>A) polymorphism and presence of
asthma, use of asthma medication or presence of allergic rhinitis at
1.5 years, 5e7 years and 11e13 years of ages after hospitalization for
bronchiolitis at age less than 6 months.Methods
Design
During two study periods in 2001e2004,187 eligible, previously
healthy, full-term infants aged less than 6 months were hospital-
ized due to bronchiolitis in the department of Pediatrics, Tampere
University Hospital, Finland.13 Clinical data, collected during hos-
pitalizations or at control visits were available from 166 patients,11
and blood samples for genetic studies were available from 165
patients.14
Bronchiolitis was deﬁned as lower respiratory infection associ-
ated with diffuse wheezes and/or crackles.13 Viral etiology of
bronchiolitis was studied with antigen detection and polymerase
chain reaction (PCR) in nasopharyngeal aspirates.13 Data on disease
severity, like need of supplementary oxygen and feeding support,
and length of hospital stay (LOS) were recorded during the inpa-
tient care.13 Information on atopic dermatitis were registered at the
post-bronchiolitis control visit at 1.5 years of age.16
The children hospitalized for bronchiolitis were later invited to
two follow-up visits. The ﬁrst was arranged in 2008e2009 when
the children were 5e7 years old.11 Before the visit the parents
completed a structured questionnaire comprising questions on
doctor-diagnosed asthma and allergic rhinitis, and previous or
current use of asthma medication and symptoms presumptive for
asthma. The follow-up study included an interview of parents to
check the questionnaire data, and bronchial hyper-reactivity was
studied in children by an exercise challenge test with impulse
oscillometry.11 In addition, data were collected on allergic rhinitis
and atopic dermatitis, and on use of corticosteroids and
bronchodilators.
The second follow-up visit was arranged in 2014e2015 when
the children were 11e13 years old. Before the visit the parents
completed a structured questionnaire comprising questions on
doctor-diagnosed asthma and allergic rhinitis, and on current use of
asthma medication and symptoms presumptive for asthma, from
the control visit at 5e7 years of age to the present. The follow-up
also included interview of children and parents to check the
questionnaire data, and a bronchodilation test. The best FEV1
(forced expiratory volume in 1 s) of three blows before and 15 min
after the inhalation of 400 mg salbutamol (Ventolin Evohaler
0.1 mg/dos, GlaxoSmithKline, London, UK), measured with ﬂow-
volume spirometry (Vmax® V62J Autobox, Becton, Dickinson, NJ,
USA) were analyzed. An increase of 12% or more in FEV1 wasregarded as a positive test result meaning a reversible airway
obstruction.
Deﬁnitions
At the control visit at age 5e7 years current asthmawas deﬁned
as a continuous or intermittent ICS use for asthma during preceding
12 months, or alternatively, as reporting of doctor-diagnosed epi-
sodes of wheezing, prolonged cough or night cough during the
preceding 12 months and a diagnostic ﬁnding in the exercise
challenge test.11 The parent-reported use of bronchodilators and
doctor-diagnosed allergic rhinitis and atopic dermatitis were
recorded if symptomatic during the past 12 months.11
At the control visit at age 11e13 years, current asthma was
considered if the child had used ICSs continuously during the last
12 months, or alternatively, if the child had suffered from repeated
wheezing or prolonged cough or night cough for four or more
weeks during the last 12 months and in addition had a diagnostic
increase of FEV1 in the bronchodilation test. The parent-reported
use of bronchodilators and doctor-diagnosed allergic rhinitis and
atopic dermatitis were recorded for the past 12 months.
Persistent asthmawas deﬁned as the presence of asthma at both
the 5e7 years and 11e13 years follow-up studies.
Genetics
Genotyping of extracted DNA for the IL-17A rs2275913
(-197G>A) gene was performed by high resolution melting anal-
ysis (HRMA) (Roche Diagnostics Light Cycler 480, Basel,
Switzerland).17 HRMA PCR reactions were run at 95 C for 10 min
followed by 45 cycles ampliﬁcation at 95 C for 10 s, at 59 C for
10 s and at 72 C for 15 s. After PCR process ﬁnal melting cycle
conditions were as outlined by Roche: ﬁrst heating to 95 C and
hold for 1 min, and cooling to pre-hold temperature (40 C) to
make sure that all PCR products have re-associated. In each run,
known (sequenced) IL-17 rs2275913 standards (wild GG type, and
heterozygous variant GA and homozygous variant AA types) were
used as controls.
Controls
The IL17A rs2275913 genotypes were determined in 405 con-
trols recruited from a study called Steps to children's healthy
development and wellbeing (Steps), which is a prospective birth
cohort study of 1827 children. The control group comprised Finnish
infants aged two to three months, who had not yet been vaccinated
(except for oral rotavirus vaccine), who were healthy, ethnic Finns,
and who visited the study clinic from 2008 to 2010.18 In controls,
genotyping from extracted DNA was performed by Sequenom
massARRAY iPlex Gold system (Sequenom, CA, USA) in the Uni-
versity of Eastern Finland, Kuopio, Finland.18
Ethics
The study was carried out in accordance with the WMA
Declaration of Helsinki. We obtained informed parental consent,
including the use of samples for genetic studies on bronchiolitis
and asthma risk both during hospitalization and at the control
visits. The protocol of the study was approved by the Ethics
committee of the Tampere University Hospital district, Tampere,
Finland. The personal data of the study subjects were not given
to the laboratory that performed the genetic studies, the
Department of Medical Microbiology and Immunology, Turku,
Finland.
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Statistical analyses were performed using the Statistic Package
of Social Science (SPSS23.0, IBM, NY, USA). Chi square and Fisher's
exact tests when appropriate, were used in the analyses of cate-
gorized variables. Student's t-test was used for normally distributed
and ManneWhitney test for non-normally distributed continuous
variables. The results were expressed as frequencies, proportional
frequencies, medians, means and standard deviations.
Logistic regressionwas used to evaluate the wild GG and variant
GA or AA genotypes as risk factors for the outcomes at 5e7 years
and 11e13 years of ages, ﬁrst as non-adjusted, and then as adjusted
for current age (continuous), sex, RSV positivity during bronchio-
litis and atopic dermatitis at less than 12 months of age. The results
were expressed as odds ratios (OR) and 95% conﬁdence intervals
(95% CI).Results
Basic data
The mean age of the 165 bronchiolitis patients was 10.71 weeks
(SD 6.82) during hospitalization, and 84 (50.6%) were boys. The
wild genotype GG of IL17A rs2275913 was present in 48 (29.1%)
children and the variant genotype in 117 (70.9%): GA in 87 (52.7%)
and AA in 30 (18.2%) cases without any signiﬁcant differences
compared to controls (Table 1). The minor (A) allele frequency
(MAF) was 0.45 (147/330) in the 165 bronchiolitis patients and 0.38
in controls (p ¼ 0.36).Hospitalization data
RSV was the causative agent in 113 (68.5%) cases. RSVwas found
in 33 (68.8%) cases if the child had the wild GG and in 81 (69.2%) if
the child had the variant GA or AA genotype (p ¼ 0.95). The mean
LOS was 4.48 days (SD 3.19, range 0e22), being 4.61 days inTable 1
Genotypes of IL17A rs2275913 polymorphisms in 165 children hospitalized for
bronchiolitis at less than 6 months of age and in 405 population-based controls.
Genotypes Bronchiolitis
N ¼ 165 (%)
Controls
N ¼ 405 (%)
p value vs. the wild
GG genotype
Wild GG 48 (29.9) 146 (36.0) e
Variant GA 87 (52.5) 181 (44.7) 0.072
Variant GA 30 (18.2) 78 (19.3) 0.563
Variant all, GA or AA 117 (70.9) 259 (64.0) 0.118
MAF 147/330 (44.5) 337/810 (38.3) 0.362
Distribution of three genotypes: p¼ 0.187 between bronchiolitis cases and controls.
Table 2
Clinical characteristic at the 5e7 years follow-up in relation to presence of the wild vs. v
Clinical characteristic Wild GG genotype
n ¼ 40 (%)
Va
n ¼
Current asthma
N ¼ 19
8 (20.0) 11
GA
Bronchodilators in last 12 months
N ¼ 26
11 (27.5) 15
GA
Inhaled steroids in last 12 months
N ¼ 18
8 (20.0) 10
GA
Allergic rhinitis in last 12 months
N ¼ 40
12 (30.0) 28
GA
Atopic dermatitis in last 12 months
N ¼ 42
13 (32.5) 29
GA
y aOR ¼ OR adjusted for age, sex, RSV and atopy at age less than 12 months.children with wild GG and 3.97 days in children with variant GA or
AA genotypes (p ¼ 0.32).
There were no signiﬁcant differences in the severity markers of
bronchiolitis, including the need and duration of oxygen adminis-
tration, or the need and duration of feeding support, between the
children with wild GG and variant GA or AA genotypes (Data not
shown).
Follow-up data at age 5e7 years
The wild genotype GG was present in 40 (28.6%) children and
the variant genotype in 100 (71.4%): GA in 75 (53.6%) and AA in 25
(17.8%) cases. There were no signiﬁcant differences in any
wheezing, asthma or allergy parameters between children with
wild GG and variant GA or AA genotypes (Table 2).
Follow-up data at age of 11e13 years
The wild genotype GG was present in 34 (27.4%) children and
the variant genotype in 90 (72.6%): GA in 67 (54.0%) and AA in 23
(18.6%) cases. In non-adjusted analyses, children with the variant
GA or AA genotype had signiﬁcantly less often current asthma, or
current allergic rhinitis, and reported less often use of ICSs in the
last 12 months, compared with those with the wild GG genotype
(Table 3).
In adjusted analyses, use of ICSs in the last 12months (aOR 0.25)
retained statistical signiﬁcance, but current asthma, current allergic
rhinitis and use of bronchodilators in last 12monthsmarginally lost
it (Table 3).
Discussion
There are three main results in the present prospective, long-
term follow-up study on the association of IL-17A rs275913 poly-
morphism with disease severity and development of asthma or
allergic rhinitis in children hospitalized for bronchiolitis at age less
than 6 months. First, we did not ﬁnd any signiﬁcant associations
between the studied polymorphism and bronchiolitis severity
during hospitalization or post-bronchiolitis outcome until 5e7
years of age. Second, we found a signiﬁcant association between
the studied polymorphism and asthma at the age of 11e13 years;
asthma by different deﬁnitions was less common in those who had
the variant GA or AA genotype of IL-17A rs2275913 polymorphism.
The ICS use for asthma during the last 12 months remained as
statistically signiﬁcant in adjusted analyses. Third, we found some
evidence for an association between the studied IL17A poly-
morphism and allergic rhinitis at 11e13 years of age.
The single nucleotide polymorphism (SNP) of IL-17A rs2275913
(-197G>A) in the promoter region of the IL-17A gene was selectedariant genotype of IL-17A rs2275913 polymorphism.
riant GA or AA genotype
100 (%)
p value ORy (95% CI) for the
variant genotype
(11.0)
¼ 8, AA ¼ 3
0.16
(15.0)
¼ 10, AA ¼ 5
0.09 0.47 (0.19e1.13)
(10.0)
¼ 8, AA ¼ 2
0.12 0.44 (0.16e1.22)
(28.0)
¼ 20, AA ¼ 8
0.81 0.91 (0.41e2.03)
(29.0)
¼ 22, AA ¼ 7
0.68 0.85 (0.39e1.87)
Table 3
Clinical characteristic at the 11e13 years follow-up in relation to presence of wild vs. variant genotype of IL-17A rs2275913 polymorphism.
Clinical characteristic Wild GG genotype
n ¼ 34 (%)
Variant GA or AA
genotype
n ¼ 90 (%)
p value OR (95% CI) for the
variant genotype
aORy (95% CI) for the
variant genotype
Current asthma
N ¼ 15
8 (23.5) 7 (7.8)
GA ¼ 7, AA ¼ 0
0.02 0.27 (0.09e0.83) 0.32 (0.10e1.04)
Persistent asthma
N ¼ 9
5 (14.7) 4 (4.4)
GA ¼ 4, AA ¼ 0
0.05 0.27 (0.07e1.07) 0.21 (0.04e1.02)
Inhaled steroids in last 12 months
N ¼ 11
6 (17.6) 5 (5.6)
GA ¼ 5, AA ¼ 0
0.04 0.28 (0.08e0.97) 0.25 (0.06e0.97)
Bronchodilator in last 12 months
N ¼ 28
12 (35.3) 16 (17.8)
GA ¼ 11, AA ¼ 5
0.04 0.40 (0.16e0.96) 0.44 (0.18e1.11)
Allergic rhinitis
N ¼ 19
9 (26.5) 10 (11.1)
GA ¼ 6, AA ¼ 4
0.03 0.35 (0.13e0.95) 0.40 (0.13e1.22)
Atopic dermatitis
N ¼ 31
9 (26.5) 29 (29.0)
GA ¼ 22, AA ¼ 7
0.82 0.90 (0.37e2.21) 0.95 (0.36e2.49)
The bold values represent that p values are signiﬁcant at level <0.05.
y aOR ¼ OR adjusted for age, sex, RSV and atopy at age less than 12 months.
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that SNP and childhood asthma,5,8,19 or between that SNP and
asthma plus allergy.20,21 The inﬂuence of different IL-17A variants
on IL-17A production is still unknown, as is also the impact of the
rs2275913 variant. In cell cultures, T cells from healthy individuals
possessing the variant A allele of IL-17A rs2275913 produced more
IL-17 than those without the A allele.22 However, the result was
opposite in the most recent study from Finland in 93 healthy in-
fants aged 13 months.18 Serum IL-17 was detectable in 6% of the
variant AA homozygotes, in 33% of the variant GA heterozygotes,
and in 75% of the wild GG homozygotes.
Dutch researchers combined clinical data from tracheal aspi-
rates of bronchiolitis patients and experimental data from human
cell cultures and an animal model of RSV infection and concluded
that early local IL-17A production in the airways during RSV
bronchiolitis facilitates neutrophil recruitment leading to neutro-
philic inﬂammation in infant lungs.23 Bronchiolitis, preschool
asthma and severe asthma later may be merely associated with
neutrophilic than eosinophilic inﬂammation.24e26 IL-17A is,
because of promoting neutrophil mobilization and further
neutrophilic inﬂammation,1,8 involved in host defense against
bacteria, and possibly, also against viruses.9
The variant IL-17A genotypes were associated with a decreased
risk of childhood asthma in a Tunisian caseecontrol study,5 which
is in agreement with our results. In disagreement, the variant ge-
notypes of IL17A genes were associated with an increased asthma
and allergy risk in different populations,19e21,27 including a study
made in Chinese children.8 The differences in the direction of the
effect of the IL-17A rs2275913 SNP between our results and some
other studies may be due to two reasons: ﬁrst, simply ethnically
different populations, or second, our selected study group with
bronchiolitis in early infancy.
The prevalence of asthma is 7e9% in the child population at
school age in Finland.28 The 23.5% prevalence of current asthma
was 3e4-fold in children with the wild GG IL-17A rs2275913 ge-
notype and about the same (7.8%) in childrenwith the variant GA or
GG genotype in the present study. Since the polymorphismwas not
associated with wheezing or asthma until 5e7 years of age, the
presence of the variant IL-17A rs2275913 genotype seemed to
promote the natural tendency that many children with early-
childhood asthma outgrow wheezing symptoms at school age.
Evidently, asthma at preschool age and in adolescence have
different risk factors, factors of innate immunity as an example.
There were certain limitations in the present study. The small
number of patients means a risk of type-2 statistical error. On the
other hand, we had a clear result that asthma risk was decreased at
11e13 years of age in those with variant IL-17A rs2275913polymorphism, and we were able to conﬁrm this result in analyses
adjusted for relevant early-life confounding factors. Thus, the po-
wer of the study was sufﬁcient for the conclusion that the variant-
type IL-17A rs2275913 polymorphism is protective for post-
bronchiolitis asthma in adolescence.
In conclusion, IL-17A rs2275913 polymorphism did not play any
signiﬁcant role in bronchiolitis that required hospitalization at less
than 6months, or in the post-bronchiolitis outcome until 5e7 years
of age. Instead, the variant genotype of IL-17A rs2275913 poly-
morphismGA or AAwas a signiﬁcant protective factor for asthma in
schoolchildren from the age 7 to 13 years.
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